Source: Feng Y, Lin CC, Rose-Nussbaumer J. The Rise of Cultured Human Corneal Endothelial Cell Therapy. JAMA Ophthalmol. 2026;144(5):478-479. doi:10.1001/jamaophthalmol.2026.0919.
American Journal of Ophthalmology Case Reports
Source: Kataoka Y, et al. Long-term outcome of cultured corneal endothelial cell transplantation with descemetorhexis: A 10-year follow-up study. Am J Ophthalmol Case Rep. 2026;41:102489. doi:10.1016/j.ajoc.2025.102489.
Japanese Journal of Ophthalmology
Source: Yamamoto Y, et al. Quality of life after cultured corneal endothelial cell transplant in patients with bullous keratopathy. Jpn J Ophthalmol. 2026;70(2):254-259. doi:10.1007/s10384-025-01280-6.
Source: Kinoshita S, et al. Long-term Corneal Rejuvenation after Transplantation of Cultured Human Corneal Endothelial Cells. Ophthalmology. 2025;132(10):1105-1113. doi:10.1016/j.ophtha.2025.05.020.
Source: Holland EJ, et al. ESCALÓN: A Prospective Randomized Trial of Corneal Endothelial Cell Therapy in Subjects With Corneal Edema. Cornea. 2025;44(12):1497-1507. doi:10.1097/ICO.0000000000003844.
Japanese Journal of Ophthalmology
Source: Ueno M, et al. Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy. Jpn J Ophthalmol. 2024;68(6):660-668. doi:10.1007/s10384-024-01123-w.
American Journal of Ophthalmology
Source: Ueno M, et al. Superiority of Mature Differentiated Cultured Human Corneal Endothelial Cell Injection Therapy for Corneal Endothelial Failure. Am J Ophthalmol. 2022;237:267-277. doi:10.1016/j.ajo.2021.11.012.
Source: Numa K, et al. Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure. Ophthalmology. 2021;128(4):504-514. doi:10.1016/j.ophtha.2020.09.002.
New England Journal of Medicine
Source: Kinoshita S, et al. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. N Engl J Med. 2018;378(11):995-1003. doi:10.1056/NEJMoa1712770.
Source: Kataoka Y, et al. Endothelial Cell Therapy for Post-Keratoplasty Corneal Endothelial Failure. Ophthalmology. Published online August 11, 2026. doi:10.1016/j.ophtha.2026.08.007.
Source: Ogino R, et al. Cultured Human Corneal Endothelial Cell Injection for Endothelial Graft Failure After DSAEK. JAMA Ophthalmol. 2026;144(5):474-478. doi:10.1001/jamaophthalmol.2026.0812.
American Journal of Ophthalmology
Source: Ogino R, et al. Cultured Human Corneal Endothelial Cell Injection Therapy in Phakic Eyes with Bullous Keratopathy. Am J Ophthalmol. Published online July 24, 2026. doi:10.1016/j.ajo.2026.07.038.
Source: Kobayashi A, et al. Longitudinal Anterior Segment Optical Coherence Tomography Imaging Findings After Cultured Human Corneal Endothelial Cell Injection Therapy (Vyznova) for Bullous Keratopathy: Twelve-Month Outcomes in Uncomplicated and Complicated Cases. Cornea Open. 2026;5(2). doi:10.1097/COA.0000000000000093.
Source: Ogino R, et al. Cultured Human Corneal Endothelial Cell Injection (Vyznova) in Eyes with Extremely Low Intraocular Pressure After Glaucoma Surgery: Case Reports. Cornea. Published online March 6, 2026. doi:10.1097/ICO.0000000000004145.
Source: Kobayashi A, et al. A Modified Long Corneal Tunnel Technique for Intracameral Injection in Cultured Human Corneal Endothelial Cell Therapy (Vyznova): A Preliminary Technical Report. Cornea. 2026;45(6):793-798. doi:10.1097/ICO.0000000000004110.
Source: Kobayashi A, et al. The “Polish Sign”: A Novel Intraoperative Visual Indicator During Descemet Membrane Polishing in Cultured Human Corneal Endothelial Cell Injection Therapy. Cornea. 2026;45(5):667-671. doi:10.1097/ICO.0000000000004092.
Source: Kobayashi A, et al. Early Clinical Outcomes of Cultured Human Corneal Endothelial Cell Injection (Vyznova) for Bullous Keratopathy: Initial Clinical Experience. Cornea. 2026;45(6):775-784. doi:10.1097/ICO.0000000000003984.
Source: Tomioka Y, et al. Guttae Morphology After Cultured Corneal Endothelial Cell Transplant in Fuchs Endothelial Corneal Dystrophy. JAMA Ophthalmol. 2024;142(9):818-826. doi:10.1001/jamaophthalmol.2024.2718.
Source: Toda M, et al. Quiescent innate and adaptive immune responses maintain the long-term integrity of corneal endothelium reconstituted through allogeneic cell injection therapy. Sci Rep. 2022;12(1):18072. doi:10.1038/s41598-022-22522-4.
Nature Biomedical Engineering
Source: Yamamoto A, et al. A physical biomarker of the quality of cultured corneal endothelial cells and of the long-term prognosis of corneal restoration in patients. Nat Biomed Eng. 2019;3(12):953-960. doi:10.1038/s41551-019-0429-9.
Investigative Ophthalmology & Visual Science
Source: Toda M, et al. Production of Homogeneous Cultured Human Corneal Endothelial Cells Indispensable for Innovative Cell Therapy. Invest Ophthalmol Vis Sci. 2017;58(4):2011-2020. doi:10.1167/iovs.16-20703.
Source: Okumura N, et al. Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction. Sci Rep. 2016;6:26113. doi:10.1038/srep26113.
American Journal of Pathology
Source: Okumura N, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol. 2012;181(1):268-277. doi:10.1016/j.ajpath.2012.03.033.
